Mangoceuticals (MGRX) shares rose ~19% in the premarket on Thursday after the telemedicine platform announced partnerships with Eli Lilly (LLY) and Novo Nordisk (NVO) to provide direct access to the pharma giants’ GLP-1 weight loss drugs.
As part of the deals, Dallas, Texas-based Mangoceuticals (MGRX) said it has launched MangoRx Direct and PeachesRx Direct to sell LLY’s (LLY) Zepbound (tirzepatide) and Novo’s (NVO) Wegovy (semaglutide) to cash-paying customers.
Additionally, patients can receive virtual consultations, personalized obesity and weight management treatment plans, and other benefits through MangoRx Direct and PeachesRx, the company added.
“For just $99/month, our medication management membership includes unlimited telehealth visits, personalized progress tracking, and lifestyle coaching,” CEO Jacob Cohen noted.
“GLP-1 medications are provided separately at fixed cash-pay pricing through LillyDirect and NovoCare programs,” he added, referring to the companies’ direct-to-consumer platforms.
The launch follows the Trump administration’s recent agreements with Eli Lilly (LLY) and Novo Nordisk (NVO) to reduce prices of the companies’ prescription medicines, including GLP-1 drugs, for Medicare, Medicaid, and self-paying customers.